---
title: "AEON cuts warrant price 38% to $0.20, below its July offering price, to collect about $6.2 million"
url: "https://aibio.space/news/aeon-cuts-warrant-price-38-percent-0-20-below-july-offering-price/"
event_date: "2026-11-03"
date_published: "2026-11-05"
description: "AEON Biopharma repriced the two-year warrants from its July offering after declaring its own FDA trigger met. The cheaper exercise brings in less per share, adds roughly 31 million shares, and comes ahead of a December 15 reverse split vote."
---

# AEON cuts warrant price 38% to $0.20, below its July offering price, to collect about $6.2 million

AEON Biopharma, Inc. (NYSE American: AEON) has cut the exercise price of the two-year milestone warrants it sold in July by about 38%, from $0.3221 to $0.20 a share, so that a group of holders will exercise before the warrants expire on November 16. Chief Executive Officer Robert Bancroft signed the 8-K filed November 3. The company expects about $6.2 million in gross proceeds. That money comes in at a price below both the July offering price and the $0.273 last sale on November 2, and it adds a large block of new shares to a company that reported a stockholders' deficit at June 30. The $6.2 million is an expectation, not cash received. [November 3 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000081/aeon-20261102x8k.htm) [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000082/aeon-20261103x424b3.htm)

## What changed

On November 2, AEON signed an Amendment to Two-Year Milestone Warrant to Purchase Common Stock or Pre-Funded Warrants with holders representing at least 67% of the shares of Class A common stock and pre-funded warrants issuable under the warrants. Effective that day, the exercise price per share fell from $0.3221 to $0.20, and the price per pre-funded warrant fell from $0.3220 to $0.1999. Each pre-funded warrant is still exercisable for one share at $0.0001. The number of shares issuable and the expiry date did not change. Under Section 5(l) of the warrants, the amendment binds every outstanding two-year warrant, including those whose holders did not sign. [November 3 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000081/aeon-20261102x8k.htm)

Certain holders that signed agreed to exercise at the reduced price, and those exercises are the source of the expected $6.2 million. At $0.20 a share, that works out to roughly 31 million shares, against 71,517,020 shares of common stock outstanding on October 30. The prospectus supplement says the repricing cuts the potential gross proceeds from cash exercise of all milestone warrants from about $29.6 million to about $24.4 million, excluding warrants issued under the underwriters' over-allotment option. The five-year milestone warrants, priced at $0.3704 a share, were not amended. [Prospectus supplement](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000082/aeon-20261103x424b3.htm)

## The July deal behind the warrants

The warrants came out of an underwritten public offering that closed on July 15, 2026, with Lake Street Capital Markets, LLC as representative of the underwriters. AEON sold 17,851,599 shares and pre-funded warrants for 24,837,008 shares at a combined price of $0.3221 per share ($0.3220 per pre-funded warrant), each with one two-year and one five-year milestone warrant. The representative exercised its option for two-year and five-year milestone warrants covering 6,403,290 shares each. AEON reported net proceeds of about $12.2 million. [July 15 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000052/aeon-20260713x8k.htm)

The November amendment names no underwriter, placement agent, financial advisor or counsel, and its only exhibits are the form of the warrant and the amendment itself. [November 3 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000081/aeon-20261102x8k.htm)

## Who decided the clock had started

Each two-year warrant expired on the earlier of July 15, 2028, or 45 days after AEON announced FDA Type 2b meeting minutes that do not preclude advancement of ABP-450 toward a Biologics License Application under the Section 351(k) biosimilar pathway. On September 30, AEON said it had reviewed the minutes and determined that they met that standard, which set the November 16 expiry. The company itself said the determination relates only to the contract wording and is not an FDA finding that ABP-450 is biosimilar to BOTOX. [September 30 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/aeon-20260930x8k.htm)

The FDA agreed in principle with a two-stage pharmacodynamic study design and made recommendations to strengthen it. AEON plans to file an IND for that study in the fourth quarter of 2026, start it in the first quarter of 2027 and return to the FDA in 2027 with an integrated evidence package. Earlier Daewoong Pharmaceutical studies may count as supportive evidence only after scientific bridging, and the FDA asked for analyses supporting the rationale for the outcome of an earlier Phase 2 migraine study. No Biologics License Application has been filed. [September 30 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/aeon-20260930x8k.htm)

In our reading, the sequence favors the warrant holders. The company declared its own trigger met, the warrants started to run out, and the price was then cut below the market to get them exercised.

## Cash, deficit and a reverse split vote

AEON's quarterly report shows cash and cash equivalents of $3,431,000 at June 30, 2026, down from $6,243,000 at March 31. Operating activities used $6,334,000 in the first half, the net loss for the half was $12,948,000, and the stockholders' deficit was $15,361,000 at June 30. Those figures predate the July offering. [Q2 10-Q](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000062/aeon-20260630x10q.htm)

Stockholders will vote on December 15, 2026, on authority for one reverse stock split at a ratio between 1-for-2 and 1-for-100, chosen by the board within 12 months. The proxy says a split would not remedy an equity, market capitalization, financial condition or operational deficiency, and that approval does not guarantee continued listing. [Proxy statement](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000074/aeon-20261026xdef14a.htm)

The next filings should show how many two-year warrants were exercised by November 16, how much cash arrived against the $6.2 million, the new share count, and whether the IND for the pharmacodynamic study goes in this quarter as planned. [November 3 8-K](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000081/aeon-20261102x8k.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/1837607/000183760726000081/aeon-20261102x8k.htm
- https://www.sec.gov/Archives/edgar/data/1837607/000183760726000082/aeon-20261103x424b3.htm
- https://www.sec.gov/Archives/edgar/data/1837607/000183760726000052/aeon-20260713x8k.htm
- https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/aeon-20260930x8k.htm
- https://www.sec.gov/Archives/edgar/data/1837607/000183760726000062/aeon-20260630x10q.htm
- https://www.sec.gov/Archives/edgar/data/1837607/000183760726000074/aeon-20261026xdef14a.htm
